18 results
Thumbnail

D1.116 - Severe Airflow Limitation Unmasked by NSAID Hypersensitivity: A Case of Undiagnosed Persistent Asthma with Nasal Polyposis

Thumbnail

D1.117 - Combing dual biologics therapy for severe asthma : a series of ten cases

Thumbnail

D1.118 - The Use of Long-Acting Muscarinic Antagonist in the Treatment of Asthma: A Latin-American 2 Specialized Asthma Center Experience

Thumbnail

D1.119 - Anti-Inflammatory Effects of miRNA-Mediated Extracellular Vesicles Derived from Mesenchymal Stem Cells in a Murine Asthma Model

Thumbnail

D1.122 - Hydrogen peroxide in exhaled breath condensate as a marker for monitoring biologic treatment response in severe asthmatic patients

Thumbnail

D1.123 - Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment

Thumbnail

D1.124 - Predictive Factors of Clinical Remission in Severe Eosinophilic Asthma Treated with Benralizumab

Thumbnail

D1.125 - Biological therapy in severe asthma: 20 years of experience at the Hospital Universitario de Burgos

Thumbnail

D1.126 - Deciphering Genetic Causal Relationships and Molecular Mechanisms Linking Multiple Allergic Diseases and Schizophrenia

Thumbnail

D1.127 - Distinct roles of Natural killer T Cells and Innate Lymphoid Cells in Type I and II airway Inflammation Induced by Viral Infection

Thumbnail

D1.128 - Dupilumab in a Child with Severe Allergic Asthma, Atopic Dermatitis, Vernal Keratoconjunctivitis, and Partial IgA Deficiency

Thumbnail

D1.129 - Bispecific Antibody Targeting IL-33 and TSLP for Treating Asthma and COPD

Thumbnail

D1.130 - Associations between Serum Clara Cell Protein 16 (CC16) and Asthma Severity in Children

Thumbnail

D1.131 - TRough levels In plasma of dUpilumab and Mepolizumab in Patients with severe astHma (TRIUMPH)

Thumbnail

D1.149 - Murine IgG1 increased y subcutaneous immunotherapy suppressed development of allergic asthma

Thumbnail

D1.150 - Study design for the saFety assessment of an Accelerated up-dosing scheme using one Strength of a native house dust mite allergen extract for subcutaneous immunoTherapy in children with allergic asthma in China (FAST II study)

Thumbnail

D1.153 - Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites

Thumbnail

D1.154 - Safety of ultra-rush immunotherapy starting protocol with the molecular extract Diater Alt a 1 mol mix